Literature DB >> 9297727

Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.

R M Hoetelmans1, P L Meenhorst, J W Mulder, D M Burger, C H Koks, J H Beijnen.   

Abstract

In this review the clinical pharmacology of HIV protease inhibitors, a new class of antiretroviral drugs, is discussed. After considering HIV protease function and structure, the development of inhibitors of HIV protease is presented. Three protease inhibitors are reviewed in more detail: saquinavir, indinavir, and ritonavir. Clinical trial results with these agents are evaluated. Furthermore, adverse effects, resistance, dosage and administration, clinical pharmacokinetics, pharmacokinetic-pharmacodynamic relationships, and drug interactions are discussed.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9297727     DOI： 10.1023/a:1008629608556

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN： 0928-1231


  22 in total

1.  Does a diol cyclic urea inhibitor of HIV-1 protease bind tighter than its corresponding alcohol form? A study by free energy perturbation and continuum electrostatics calculations.

Authors:  L Wang; Y Duan; P Stouten; G V De Lucca; R M Klabe; P A Kollman
Journal:  J Comput Aided Mol Des       Date:  2001-02       Impact factor: 3.686

2.  Design of dimerization inhibitors of HIV-1 aspartic proteinase: a computer-based combinatorial approach.

Authors:  A Caflisch; H J Schramm; M Karplus
Journal:  J Comput Aided Mol Des       Date:  2000-02       Impact factor: 3.686

Review 3.  The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.

Authors:  H A Bardelmeijer; O van Tellingen; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2000-08       Impact factor: 3.850

Review 4.  Drug interactions between antiretroviral drugs and comedicated agents.

Authors:  Monique M R de Maat; G Corine Ekhart; Alwin D R Huitema; Cornelis H W Koks; Jan W Mulder; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

5.  Saquinavir inhibits early events associated with establishment of HIV-1 infection: potential role for protease inhibitors in prevention.

Authors:  Martha Stefanidou; Carolina Herrera; Naomi Armanasco; Robin J Shattock
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

6.  Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir.

Authors:  G J Muirhead; M B Wulff; A Fielding; D Kleinermans; N Buss
Journal:  Br J Clin Pharmacol       Date:  2000-08       Impact factor: 4.335

7.  Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture.

Authors:  M Nascimbeni; C Lamotte; G Peytavin; R Farinotti; F Clavel
Journal:  Antimicrob Agents Chemother       Date:  1999-11       Impact factor: 5.191

Review 8.  The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic.

Authors:  Samuel Broder
Journal:  Antiviral Res       Date:  2009-12-16       Impact factor: 5.970

9.  Effect of alpha1-acid glycoprotein on the intracellular accumulation of the HIV protease inhibitors saquinavir, ritonavir and indinavir in vitro.

Authors:  K Jones; P G Hoggard; S Khoo; B Maher; D J Back
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

Review 10.  Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant women.

Authors:  Matthieu Roustit; Malik Jlaiel; Pascale Leclercq; Françoise Stanke-Labesque
Journal:  Br J Clin Pharmacol       Date:  2008-05-15       Impact factor: 4.335
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.